# Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management

> **NCT02315287** · PHASE4 · UNKNOWN · sponsor: **Seoul National University Bundang Hospital** · enrollment: 190 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Pioglitazone
- **DRUG:** Lobeglitazone

## Key facts

- **NCT ID:** NCT02315287
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02315287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02315287, "Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02315287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*